Literature DB >> 15519482

Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience.

Octavian C Ioachimescu1, Adriana G Ioachimescu, Paul B Iannini.   

Abstract

Multiple severity scoring systems have been devised and evaluated in community-acquired pneumonia (CAP), but a simplified set of prognostic indicators has not yet been developed. Streptococcus pneumoniae is the most frequent aetiological agent of CAP. Our aim was to characterise the outcome in the light of different severity scoring systems and to compare the predictive values of different sets of clinical parameters, using available clinical data for pneumococcal CAP patients. This is a case series retrospective analysis that included consecutive adult pneumococcal CAP patients admitted to Danbury Hospital between 1 January 1996 and 31 December 2000. The aetiology was confirmed by positive sputum and/or blood cultures. The severity assessment included the Pneumonia Outcome Research Trial (PORT) and British Thoracic Society (BTS) scoring systems and other additional parameters. Primary end-points were in-hospital CAP-attributable deaths and length of hospitalisation. N = 151 patients with S. pneumoniae CAP were identified. The mean (+/- standard deviation) age at the time of diagnosis was 68 (+/-15) years. Thirty-three patients (22%) were admitted to the medical intensive care unit. The mean (median) hospitalisation duration was 7.5 (+/-5) days. Door-to-antibiotic mean (median) administration time was 3.7 (2) hours. Most frequent antibiotics used initially were cephalosporins plus/minus macrolides or fluoroquinolones. The mean (+/- standard deviation) PORT score was 105 (+/-37). The observed CAP-related mortality was 9/151 (5.9%, 95% confidence interval: 3-9%). The mortality rate in ICU was 18% (6/33). Sixty-nine patients (45%) had S. pneumoniae bacteraemia an admission. The bacteraemic and non-bacteraemic patients had similar PORT scores (107 vs. 104, P = 0.66), length of hospitalisation (8 vs. 7 days, P = 0.41) and mortality rates (9% vs. 4%, P = 0.30). In conclusion, patients admitted with pneumococcal CAP, although severe and with multiple co-morbidities had low in-hospital mortality rates and lengths of hospitalisation. Neither prior antimicrobial use (or failure) nor antimicrobial resistance contributed to an adverse outcome. S. pneumoniae bacteraemia failed to correlate with need for ICU, length of stay, higher morbidity index or fatal outcome. Low rates of empirical antibiotic use for non-bacterial infections in the local community, implementation of an emergency department protocol for CAP therapy, early recognition of higher risk patients and placement in ICU, use of broad spectrum antibiotics, infectious disease approval or critical pathway restriction for admission orders, could all have combined to effect a good outcome for these patients.

Entities:  

Mesh:

Year:  2004        PMID: 15519482     DOI: 10.1016/j.ijantimicag.2004.05.006

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  12 in total

1.  Reorganising the pandemic triage processes to ethically maximise individuals' best interests.

Authors:  Andrew Tillyard
Journal:  Intensive Care Med       Date:  2010-08-06       Impact factor: 17.440

2.  Macrolide use in the treatment of critically ill patients with pneumonia: Incidence, correlates, timing and outcomes.

Authors:  Wendy I Sligl; Holly Hoang; Dean T Eurich; Atul Malhotra; Thomas J Marrie; Sumit R Majumdar
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

Review 3.  [Assessment, triage, and follow-up of a patient with: acute CAP COPD].

Authors:  K Faure
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

4.  The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine.

Authors:  Adrienne Morrow; Philippe De Wals; Geneviève Petit; Maryse Guay; Lonny James Erickson
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-03       Impact factor: 2.471

5.  The International Community-Acquired Pneumonia (CAP) Collaboration Cohort (ICCC) study: rationale, design and description of study cohorts and patients.

Authors:  Phyo Kyaw Myint; Chun Shing Kwok; Sumit R Majumdar; Dean T Eurich; Allan B Clark; Pedro P España; Shin Yan Man; David T Huang; Donald M Yealy; Derek C Angus; Alberto Capelastegui; Timothy H Rainer; Thomas J Marrie; Michael J Fine; Yoon K Loke
Journal:  BMJ Open       Date:  2012-05-21       Impact factor: 2.692

Review 6.  Severe community-acquired pneumonia.

Authors:  Wendy I Sligl; Thomas J Marrie
Journal:  Crit Care Clin       Date:  2013-07       Impact factor: 3.598

7.  Circulating sphingosine-1-phosphate as a prognostic biomarker for community-acquired pneumonia.

Authors:  Shih-Chang Hsu; Jer-Hwa Chang; Yuan-Pin Hsu; Kuan-Jen Bai; Shau-Ku Huang; Chin-Wang Hsu
Journal:  PLoS One       Date:  2019-05-15       Impact factor: 3.240

8.  High GRP78 levels in Covid-19 infection: A case-control study.

Authors:  Ramazan Sabirli; Aylin Koseler; Tarik Goren; Ibrahim Turkcuer; Ozgur Kurt
Journal:  Life Sci       Date:  2020-11-19       Impact factor: 5.037

Review 9.  Pro/Con debate: should 24/7 in-house intensivist coverage be implemented?

Authors:  Yaseen Arabi
Journal:  Crit Care       Date:  2008-06-05       Impact factor: 9.097

10.  Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.

Authors:  Jacopo Maria Legramante; Maria Mastropasqua; Beniamino Susi; Ottavia Porzio; Marta Mazza; Grazia Miranda Agrippino; Cartesio D Agostini; Antonella Brandi; Germano Giovagnoli; Vito Nicola Di Lecce; Sergio Bernardini; Marilena Minieri
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.